Scope and Claim Coverage of U.S. Patent 10,189,837: Crystalline Tosylate Salt Specifications for (8S,9R)-5-Fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-8,9-dihydro-2H-pyrido[4,3,2-de]phthalazin-3(7H)-one
U.S. Patent 10,189,837 is a crystalline form patent that restricts protection to a specific salt identity (tosylate) tied to tight, instrument-defined solid-state characterization. The independent claim anchors the invention to a crystalline tosylate salt defined by an X-ray powder diffraction (XRPD) peak set at 2θ of 7.5, 20.1, and 24.1 (each within ±0.2). Dependent claims broaden coverage across alternate XRPD peak sets and add a second orthogonal characterization gate using solid-state 13C NMR peaks (each within ±0.2 ppm). Claim 4–6 extend the salt into pharmaceutical compositions via use of the characterized solid with excipients, without adding additional solid-state constraints.
What claims define the crystalline tosylate salt in U.S. Patent 10,189,837?
What is the active moiety and what exact salt is claimed?
The claims define a crystalline tosylate salt of a single, stereochemically specified compound:
- (8S,9R)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-8,9-dihydro-2H-pyrido[4,3,2-de]phthalazin-3(7H)-one
The salt counterion is p-toluenesulfonate (tosylate). The claims do not attempt to cover “any salt” or “any crystalline form of the free base.” They narrow to “crystalline tosylate salt” plus the specific solid-state signature.
What is the independent claim scope (Claim 1)?
Claim 1 is the claim that sets the enforceable boundary. It covers:
- The crystalline tosylate salt of the specified (8S,9R) compound
- Where the material has an XRPD pattern with peaks at:
- 2θ = 7.5° ± 0.2°
- 2θ = 20.1° ± 0.2°
- 2θ = 24.1° ± 0.2°
The structure is typical of “Form-by-analytics” patenting. The claim does not require exclusive presence of those peaks, but in practice infringement risk turns on whether an accused product’s measured pattern includes those peaks at those positions within tolerance under comparable measurement conditions.
What is the practical meaning of the ±0.2 tolerances?
The claim’s tolerances act as a measurement envelope:
- XRPD peak positions must be within ±0.2° of the listed 2θ values.
- Solid-state NMR chemical shifts in dependent Claim 3 must be within ±0.2 ppm.
This creates two litigation-relevant fault lines:
- Instrument and method matching: XRPD conditions (radiation source, scan speed, step size, background subtraction, sample prep) can shift apparent peak maxima by tenths of a degree.
- Polymorph or solvate substitution: a different crystalline form, different counterion, or mixture may fail the peak positional requirements even if it is still “a crystalline tosylate salt” in a generic sense.
What do dependent claims add?
Claim 2 tightens the XRPD profile further by requiring an expanded set of peaks:
- 2θ = 7.5° ± 0.2°
- 15.1° ± 0.2°
- 18.1° ± 0.2°
- 20.1° ± 0.2°
- 20.5° ± 0.2°
- 22.6° ± 0.2°
- 24.1° ± 0.2°
Claim 3 introduces a second, independent solid-state identity gate using solid state 13C NMR:
- 143.2 ppm ± 0.2
- 136.0 ppm ± 0.2
- 131.8 ppm ± 0.2
- 123.9 ppm ± 0.2
- 112.2 ppm ± 0.2
- 105.2 ppm ± 0.2
- 100.3 ppm ± 0.2
Claim 4–6 convert the characterized salt into covered downstream products:
- Claim 4: pharmaceutical composition containing the salt of Claim 1 + excipient
- Claim 5: pharmaceutical composition containing the salt of Claim 3 + excipient
- Claim 6: pharmaceutical composition containing the salt of Claim 2 + excipient
No additional limitations are stated for dosage form, route, or excipient identity.
How do Claims 1–3 interact as an “XRPD gate + orthogonal NMR gate” structure?
Does Claim 2 expand or narrow coverage vs Claim 1?
Claim 2 is narrower than Claim 1 because it requires additional peak positions. In infringement terms:
- A product that matches Claim 2 necessarily matches the peaks required by Claim 1 at least for the overlapping 7.5°, 20.1°, and 24.1° entries.
- A product may match Claim 1 but not Claim 2 if it lacks one or more of the additional peaks (15.1°, 18.1°, 20.5°, 22.6°).
Claim 2 is best viewed as a higher-specificity “Form sub-profile” hedge.
Why add Claim 3 (solid-state 13C NMR) on top of XRPD?
Claim 3 is a classic attempt to reduce “design-around by shifting XRPD” risk:
- If a competitor changes processing conditions to get a slightly different XRPD (within measurement noise), the NMR peaks provide an alternate check.
- If a competitor uses XRPD matching but retains different crystallographic packing, NMR can still diverge.
In litigation, having two characterization modalities increases the likelihood that an accused product will be pinned to the claimed solid state or, conversely, that challengers must produce strong counter-evidence.
Are Claim 1 and Claim 3 mutually inclusive?
They are not written as “either/or” but as separate claim bases:
- Claim 1 does not require the NMR peak list.
- Claim 3 does not require the XRPD peak list.
Both are independently enforceable routes. If a product matches one set of analytics, it can fall within the corresponding claim.
What does this imply for competitor solid form strategy?
A competitor seeking to avoid coverage would need to:
- Use a different counterion (not tosylate), or
- Use a different crystalline form (different XRPD peak positions beyond tolerance), and
- Also aim for a solid-state 13C NMR spectrum that does not include the listed chemical shifts within ±0.2 ppm.
Because the claims are form-specific by analytics, the most viable design-around is usually either counterion change or a distinct polymorphic form with different XRPD and different NMR signatures.
What does the patent likely cover and what does it not cover based on the claim text?
Covered: crystalline form, counterion, and analytics
The patent claims a specific solid-state material:
- A crystalline tosylate salt of the specified chiral compound
- Identified by XRPD peak positions (and optionally by expanded XRPD and/or solid-state 13C NMR peaks)
- Plus compositions that include those salts and excipients.
Not covered: non-crystalline solids, amorphous forms, or other salts
The claims do not cover:
- Amorphous tosylate
- Any other polymorph of the tosylate not meeting the XRPD positional constraints
- Solvates/hydrates unless they still meet the exact XRPD peak set
- Salts other than tosylate (e.g., hydrochloride, mesylate, acetate) because “tosylate” is explicit
- The free base form without the tosylate counterion
Not covered: dosage forms or administration methods
Claims 4–6 do not restrict:
- Dosage form (tablet, capsule, suspension)
- Route (oral, parenteral)
- Release profile (immediate vs extended)
- Dosing regimen
So once the claimed salt is used in any formulation, the composition claims are at least facially implicated.
How strong is the enforceable coverage for U.S. Patent 10,189,837?
Strength drivers
-
Tight peak-position constraints
XRPD peaks at 7.5°, 20.1°, 24.1° with ±0.2° tolerance establish a clear metrology-based boundary.
-
Multiple characterization modalities
Claim 3 adds solid-state 13C NMR peak constraints. This reduces the ease of countering with “XRPD-only” differences.
-
Downstream composition claims
Claim 4–6 provide a second layer: even if a party argues about how the salt is characterized in isolation, the moment it is incorporated into a pharmaceutical composition, those claims become relevant.
Litigation vulnerability points (where challenges often focus)
-
Measurement reproducibility and method alignment
XRPD and solid-state NMR are sensitive to test conditions. Defendants often attack peak assignment, baseline, and sample preparation.
-
Product heterogeneity
If the accused material is a mixture of crystalline forms or contains polymorphs that generate additional or shifted peaks, it may either:
- still infringe if the required peaks appear at correct positions, or
- avoid infringement if the material does not produce peaks within the required tolerance.
-
Prior-art crystalline form disclosures
Although the claim is narrow, crystalline form patents can be challenged if prior art discloses the same salt and the same analytical signature or provides enabling disclosure to arrive at it.
What patents typically cluster around a crystalline form salt like this?
For a chiral heterocycle API with defined XRPD/NMR peaks, the usual surrounding landscape (in related programs) is:
- API composition / core structure patents (compound claims covering the free base and/or salts broadly)
- Stereochemistry and intermediate patents covering the (8S,9R) configuration and key intermediates
- Salt selection patents (tosylate identified among multiple salts)
- Polymorph patents (Form A/B/C, solvates, hydrates) each with XRPD characterization
- Process patents for crystallization and isolation (mother liquor conditions, solvents, cooling rates)
- Formulation patents (tableting, coatings, sustained release), typically after the salt is selected
U.S. Patent 10,189,837 appears positioned as a salt crystallinity/Form patent rather than a broad core compound patent.
How does the claim drafting impact generic entry risk scenarios?
Generic risk is high if ANDA/cGMP uses the same salt form
A generic manufacturer using the same API salt form (tosylate crystalline form matching the listed XRPD peaks and/or NMR peaks) faces:
- literal infringement exposure on the salt claims
- composition infringement exposure on formulation-containing products
Risk can be reduced by switching crystal form or salt identity
Practical design-arounds include:
- switching from tosylate to a different counterion
- switching to a distinct polymorph or solvate with different XRPD maxima and different solid-state NMR peaks
- using a form that fails the specific peak positional tolerances
Because the claims are by analytics, even small differences in crystal packing or counterion can move peak positions out of the ±0.2 window.
What information is missing to map expiration, Orange Book status, or Paragraph IV litigation?
No filing date, assignee, prosecution history, related patents (continuations/divisionals), or Orange Book listings were provided in the request. Without those, it is not possible to produce an accurate US exclusivity timeline, identify co-owned/overlapping patents, or determine whether U.S. Patent 10,189,837 is listed in FDA’s Orange Book for a specific NDA/ANDA product and strength rating.
Key Takeaways
- U.S. Patent 10,189,837 protects a crystalline tosylate salt defined by XRPD peak positions (Claim 1) and reinforced by expanded XRPD (Claim 2) and solid-state 13C NMR (Claim 3).
- Claim 1 is the core boundary: XRPD peaks at 7.5°, 20.1°, and 24.1° (±0.2° each).
- Claim 2 is a narrower “peak-set expansion” dependent claim requiring additional XRPD peaks at 15.1°, 18.1°, 20.5°, and 22.6° (±0.2° each).
- Claim 3 provides an orthogonal analytical identity gate via solid-state 13C NMR peaks at 143.2, 136.0, 131.8, 123.9, 112.2, 105.2, and 100.3 ppm (±0.2 ppm each).
- Claims 4–6 extend protection to pharmaceutical compositions containing the claimed salt forms plus excipients, without additional formulation limits.
- The enforceability hinges on analytical proof of peak position compliance and on whether a competitor can shift XRPD and NMR signatures by changing solid form or salt identity.
FAQs
-
Can a competitor infringe U.S. Patent 10,189,837 if their product is a different polymorph of the tosylate?
Infringement depends on whether the accused polymorph still exhibits the required XRPD peak positions within ±0.2° (and, for Claim 3, whether the solid-state 13C NMR peaks also match within ±0.2 ppm).
-
Does the patent cover any tosylate salt, or only a specific crystalline form?
Only the crystalline tosylate salt that matches the specified analytical signatures is claimed.
-
Do the composition claims require additional formulation characteristics like sustained release or specific excipients?
No. Claims 4–6 require only the characterized salt plus a pharmaceutically acceptable excipient.
-
Is there a meaningful design-around by changing from tosylate to another counterion?
Yes. The claims explicitly require a tosylate counterion, so other salts are outside the claim scope.
-
Which analytical test is most central for infringement analysis: XRPD or solid-state NMR?
XRPD is central because it defines the independent Claim 1. Solid-state 13C NMR is central for Claim 3 and provides additional infringement hooks or verification constraints.
References
(No references provided or identifiable from the user-provided claim text alone.)
